In vitro antitumor activity of a new platinum complex, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3 -dioxolane]platinum(II) (SKI 2053R), against human lung and stomach cancer cell lines

W. S. Hong, H. T. Kim, K. H. Kim, D. K. Kim

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

The in vitro antitumor activity of a new platinum complex, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) (SKI 2053R, NSC D644591), cisplatin (CDDP) and carboplatin (CBDCA) was determined against two human lung cancer (PC-9 and PC-14) and two human stomach cancer (MKN-45 and KATO III) cell lines by human tumor clonogenic assay. The activity of SKI 2053R was compared with those of CDDP and CBDCA in terms of relative antitumor activity (RAA, peak plasma concentration/IC50). Mean IC50 values (μg/ml) of SKI 2053R, CDDP and CBDCA were 6.4 ± 0.8, 1.8 ± 0.7 and 20.6 ± 12.2, respectively. The RAAs of SKI 2053R, CDDP and CBDCA were 1.6 ± 0.4, 2.0 ± 0.8 and 1.2 ± 0.6, respectively. The differences in these values were not statistically significant. The results, demonstrating that antitumor activity, of SKI 2053R is similar to those of CDDP and CBDCA, suggest that SKI 2053R is an interesting candidate for further development as a new anticancer drug.

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalAnticancer Research
Volume15
Issue number1
StatePublished - 1995

Keywords

  • Human lung and stomach cancer cell lines
  • Human tumor clonogenic assay
  • New platinum complex (SKI 2053R)

Fingerprint

Dive into the research topics of 'In vitro antitumor activity of a new platinum complex, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3 -dioxolane]platinum(II) (SKI 2053R), against human lung and stomach cancer cell lines'. Together they form a unique fingerprint.

Cite this